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Transplantable murine models of ovarian high grade serous carcinoma (HGSC) remain an important 
research tool. We previously showed that ID8, a widely-used syngeneic model of ovarian cancer, lacked 
any of the frequent mutations in HGSC, and used CRISPR/Cas9 gene editing to generate derivatives 
with deletions in Trp53 and Brca2. Here we have used one ID8 Trp53−/− clone to generate further 
mutants, with additional mutations in Brca1, Pten and Nf1, all of which are frequently mutated or 
deleted in HGSC. We have also generated clones with triple deletions in Trp53, Brca2 and Pten. We show 
that ID8 Trp53−/−;Brca1−/− and Trp53−/−;Brca2−/− cells have defective homologous recombination 
and increased sensitivity to both platinum and PARP inhibitor chemotherapy compared to Trp53−/−. 
By contrast, loss of Pten or Nf1 increases growth rate in vivo, and reduces survival following cisplatin 
chemotherapy in vivo. Finally, we have also targeted Trp53 in cells isolated from a previous transgenic 
murine fallopian tube carcinoma model, and confirmed that loss of p53 expression in this second model 
accelerates intraperitoneal growth. Together, these CRISPR-generated models represent a new and 
simple tool to investigate the biology of HGSC, and the ID8 cell lines are freely available to researchers.
HGSC is the commonest subtype of epithelial ovarian cancer and accounts for approximately 80% of ovarian 
cancer deaths. It is marked by universal TP53 mutation1 and extreme genomic instability2,3. Approximately 20% 
HGSC harbour mutations in BRCA1 or BRCA24, whilst loss of NF1 and PTEN expression is seen in around 20% 
cases, largely resulting from complex genomic rearrangements and structural variation5. Importantly, the com-
plexity of HGSC means that multiple genomic abnormalities can co-exist within individual tumours5. Although 
robust prognostic and predictive molecular classifiers of HGSC remain elusive, patients with germline BRCA1 
and BRCA2 mutations have improved overall prognosis6 with improved response to platinum7 and PARP inhibi-
tor8 chemotherapy. Conversely, PTEN loss is a marker of poor prognosis9.
Lack of reliable immunocompetent murine models has significantly impeded HGSC research10. Recently, 
new genetically engineered mouse models (GEMM) of HGSC have been developed11,12, in which Trp53, Brca1, 
Brca2, Pten and Nf1 have been deleted in fallopian tube epithelial cells using Cre-mediated recombination. These 
models have great potential to expand our understanding of HGSC biology, but still require large-scale breeding 
programmes, and the mice can take many months to develop tumours. Thus, transplantable models remain val-
uable research tools.
First described in 200013, the ID8 model is a widely-used syngeneic model of ovarian cancer. However, using 
whole-exome sequencing, we recently showed that ID8 lacked any mutations fundamental in HGSC biology14: 
ID8 cells were Trp53 wild-type and retained functional p53 signalling. Brca1 and Brca2 were both wild-type and 
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ID8 displayed competent homologous recombination DNA double strand break repair. Using CRISPR/Cas9 gene 
editing, we generated four Trp53−/− and two Trp53−/−;Brca2−/− ID8 clones and characterised their intraperitoneal 
growth14.
We have now targeted three more genes critical in HGSC, Brca1, Pten and Nf1, in ID8 Trp53−/− cells, and have 
also generated lines with triple deletion in Trp53, Brca2 and Pten. We have evaluated sensitivity to platinum and 
PARP inhibitor therapy in these cells, as well as our original Trp53−/− and Trp53−/−;Brca2−/− cells. We have also 
targeted Trp53 in cells isolated from a previous transgenic murine fallopian tube carcinoma model15, in which Cre 
recombinase, under the control of the anti-Mullerian hormone type 2 receptor promoter (Amhr2-Cre), was used 
to delete Dicer, a key processor of microRNAs, and Pten selectively in the fallopian tube.
Our results indicate that loss of NF1 or PTEN expression increases intraperitoneal growth in ID8 cells, and 
is associated with a poor outcome following platinum chemotherapy. The utility of these ID8 derivatives is con-
firmed by increased sensitivity to both PARP inhibitor and platinum chemotherapy upon loss of BRCA1 or 
BRCA2 function. In the fallopian tube Dicer;Pten double knockout (DKO) cells, loss of p53 significantly increases 
intraperitoneal growth.
Results
CRISPR/Cas9 Brca1, Nf1 and Pten editing in ID8 cells. We used one ID8 Trp53−/− clone (F3)14 to 
generate new sublines with deletions in Brca1, Pten and Nf1. We first targeted the Brca1 PALB2-binding domain 
in exon 12 (guide 1) and the BRCT-2 domain in exon 19 (guide 6) (Fig. 1A). Three single cell clones with bi-allelic 
deletions were isolated following transfection with the two separate guide RNA (clones 1.26, 1.36 - guide 1; clone 
6.20 - guide 6; Fig. S1). All three clones failed to generate RAD51 foci in response to 10 Gy irradiation (Fig. 1B) or 
10 µM rucaparib (Fig. S2), thus fulfilling criteria for defective homologous recombination (HR)16.
We targeted exon 5 of Pten, encoding the phosphatase domain (Fig. 2A). Four clones with bi-allelic deletions 
(clones 1.11, 1.12, 1.14, 1.15) and two with single allele deletions (clones 1.9, 1.10) were isolated - deletions ranged 
from 2 bp to >400 bp (Fig. S3). Immunoblots showed absent PTEN in Trp53−/−;Pten−/− cells compared to F3, 
with reduced levels in the heterozygote clones (Fig. 2B). Bi-allelic Pten loss resulted in marked increases in AKT 
phosphorylation at both S473 and T308 upon serum starvation (Fig. 2B). AKT phosphorylation was less marked 
in one of the heterozygote clones (1.10) than in Trp53−/−;Pten−/−, although still greater than in F3 control.
For Nf1, we targeted exon 2 (Fig. 2C), and used a combination of NF1 expression on immunoblot (Fig. 2D), 
Raf-RBD co-immunoprecipitation and ERK phosphorylation (Fig. 2E) to screen clones. Clones 1.20, 1.23, 1.30 
and 1.56 all had confirmed bi-allelic deletions on Sanger sequencing, whilst 1.6 and 1.58 had single allele changes. 
We selected two clones (1.20 and 1.23; see Fig. S4 for sequencing data) for further evaluation as they demon-
strated increased GTP-bound RAS compared to F3, indicative of activated RAS signalling, as well as increased 
ERK phosphorylation on immunoblot (Fig. 2E). All Trp53−/−;Nf1−/−, Trp53−/−;Pten−/− and Trp53−/−;Pten+/− 
cells were HR competent in 10 Gy irradiation experiments (Figs 2F and S5).
Generation of triple-deleted ID8 lines. Multiple genomic abnormalities can co-exist within one HGSC 
tumour5,17. In addition, several of the GEMM require deletion of three genes for reliable tumorigenesis11,12. 
Therefore, we elected to target Pten in two of our previous Trp53−/−;Brca2−/− clones (2.14 and 3.1514) to generate 
triple deleted lines. Two clones with bi-allelic alterations (Fig. S6) were generated (2.14.22 and 3.15.10) or no 
alterations (2.14.10, 3.15.7). The triple deleted clones lacked PTEN expression on immunoblot (Fig. 3A), and 
again showed marked increases in AKT phosphorylation at both S473 and T308 upon serum starvation (Fig. 3A). 
Of note, the triple-deleted cells did not generate RAD51 foci formation in response to 10 Gy irradiation, suggest-
ing that absent PTEN expression did not alter the defective HR induced by Brca2 loss (Fig. 3B).
In vivo tumorigenesis. We then assessed intraperitoneal growth in female C57Bl/6 mice using at least 
two separate clones for each new genotype (Fig. 4A). Previously we showed that loss of p53 function signifi-
cantly increased the rate of growth of intraperitoneal ID8 compared to parental controls, whilst additional loss of 
BRCA2 expression slowed growth relative to p53 loss alone. Results here showed that there was no difference in 
survival for mice bearing Trp53−/−;Brca1−/− tumours compared to Trp53−/− (median time to reach humane end-
point 46 and 47 days respectively, p = NS), but deletion of either Pten or Nf1 expression significantly accelerated 
growth compared to p53 loss alone (Trp53−/−;Pten−/− 34 days, p < 0.0001; Trp53−/−;Nf1−/− 36.5 days, p < 0.0001). 
Survival of mice bearing heterozygote Trp53−/−;Pten+/− tumours (40.5 days) lay between that of Trp53−/− and 
Trp53−/−;Pten−/−, although differences were not significant (Fig. S7). The triple-deleted tumours showed accel-
erated growth (median time to reach humane endpoint 40 days) compared to both Trp53−/− (p = 0.003) and 
Trp53−/−;Brca2−/− p = 0.0002), but slower than Trp53−/−;Pten−/− (p = 0.0024).
Platinum and PARP inhibitor sensitivity. We then investigated the effects of specific mutations in 
the ID8 cells upon sensitivity to the PARP inhibitor rucaparib in vitro, and to platinum chemotherapy both 
in vitro and in vivo. Both Trp53−/−;Brca1−/− and Trp53−/−;Brca2−/− cells were significantly more sensitive to 
rucaparib than F3 Trp53−/− (Fig. 4B, Table 1), whilst loss of Pten and Nf1 function individually had no effect 
on rucaparib sensitivity. There was no overall difference between the sensitivity of Trp53−/−−/−;Brca1−/− and 
Trp53−/−;Brca2−/− cells. However, the Brca1 BRCT-2 domain clone (6.20) was significantly less sensitive than 
both Brca1 Palb2-binding domain mutants (1.26, 1.36) and the Trp53−/−;Brca2−/− cells, which also have a deletion 
in the Palb2-binding domain (Fig. 4B). Loss of PTEN expression did not have a significant impact upon rucaparib 
sensitivity in the Trp53−/−;Brca2–/−;Pten−/− cells compared to Trp53−/−;Brca2−/− (Fig. 4B).
A similar pattern was seen for cisplatin in vitro. Both Trp53−/−;Brca1−/− and Trp53−/−;Brca2−/− cells were 
significantly more sensitive than F3 Trp53−/− cells, whilst loss of PTEN and NF1 expression again had no effect 
(Fig. 3C, Table 1). As with rucaparib, the Palb2-binding domain mutants in both Brca1 and Brca2 were more 
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sensitive than the Brca1 BRCT-2 mutant (Fig. 4C). Interestingly, there was a significant reduction in cisplatin 
sensitivity in the triple deleted Trp53−/−;Brca2−/−;Pten−/− cells compared to Trp53−/−;Brca2−/− (Fig. 4C).
In vivo, there was a wide variation in survival following three doses of intraperitoneal cisplatin (5 mg/kg on days 
28, 35 and 42 only). Mice bearing control Trp53−/− tumours took a median of 81 days to reach humane endpoints 
(Fig. 4D, Table 2). Trp53−/−;Pten−/− and Trp53−/−;Nf1−/− tumours produced the worst survival (median 69 and 71 
days respectively; p < 0.0001 and p = 0.0001 respectively compared to Trp53−/−). For Trp53−/−;Brca1−/−, survival was 
extended to 97 days (p = 0.0003 compared to Trp53−/−), whilst the longest survival was seen with Trp53−/−;Brca2−/− 
tumours (median 113 days), which was significantly longer than both Trp53−/− and Trp53−/−;Brca1−/− (p < 0.0001 
for both comparisons). Mice bearing the triple-deleted Trp53−/−;Brca2−/−;Pten−/− tumours survived 99 days, which 
was significantly more than Trp53−/− (p < 0.0001; Table 2) but less than Trp53−/−;Brca2−/−, although this latter com-
parison did not reach statistical significance (p = 0.078). In the Trp53−/−;Brca1−/− experiments, median survival for 
the PALB2 mutant (clone 1.36) was longer (97 days) than for the BRCT-2 mutant (clone 6.20; 89 days), although 
again this did not reach statistical significance (p = 0.066) (Fig. S8).
Trp53 knockout in Dicer−/−;Pten−/− DKO cells. Finally, we targeted Trp53 in OvidT 497 Dicer−/−;Pten−/− 
DKO fallopian tube carcinoma cells using the same guide RNA used to generate ID8 Trp53−/− clone F3. Triple knockout 
(TKO; Dicer−/−;Pten−/−;Trp53−/−) clone 13 had a biallelic deletion in exon 5 (Fig. S8), with absent p53 on immunoblot, 
Figure 1. Generation of Trp53−/−;Brca1−/− ID8 cells. (A) Design of guide RNA targeted to exons 12 and 
19 of Brca1. Nucleotides in red represent PAM sequence. Schematic representation of BRCA1 protein with 
exons 12 and 19 highlighted in red (bottom). Numbers represent amino acid positions. (B) ID8 Trp53−/− and 
Trp53−/−;Brca1−/− cells were irradiated (10 Gy), fixed and stained for γH2AX and RAD51, and counterstained 
with DAPI. RAD51 foci were counted in up to 30 untreated and irradiated cells. Bars represent mean (+/− 
SEM) γH2AX (left) and RAD51 (right) foci per cell; dotted lines represents two-fold increase in γH2AX and 
RAD51 foci/cell relative to untreated cells, suggestive of induction of DNA double strand breaks and functional 
homologous recombination respectively16.
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Figure 2. Generation of Trp53−/−;Nf1−/− and Trp53−/−;Pten−/− ID8 cells. (A) Design of guide RNA targeted to 
exon 5 of Pten. Nucleotides in red represent PAM sequence. Schematic representation of PTEN protein with exon 
5 highlighted in red (bottom). Numbers represent amino acid position. (B) Immunoblot for PTEN and phospho-
AKT in clones following Pten gRNA transfection. Clones 1.11, 1.12, 1.14 and 1.15 had bi-allelic Pten deletions 
and showed absent PTEN protein with phosphorylation of AKT at both S473 and T308 following serum 
starvation. Clones 1.9 and 1.10 had mono-allelic deletions. F3 = ID8 Trp53−/−. (C) Design of guide RNA targeted 
to exon 2 of Nf1 as previously29. Nucleotides in red represent PAM sequence. Schematic representation of Nf1 
protein with exon 2 highlighted in red (bottom). Numbers represent amino acid positions. (D) Immunoblot for 
Nf1 in clones following Nf1 gRNA transfection. *; clones 1.20 and 1.23 had bi-allelic indels confirmed by Sanger 
sequencing, ^; clone 1.6 had single allele deletion. Clones 1.2, 1.3, 1.4, 1.7 and 1.17 were not sequenced. (E) Ras-
GTP co-immunoprecipitation and phospho-ERK immunoblot in ID8 clones following Nf1 gRNA transfection. 
*; clones 1.20, 1.23, 1.30 and 1.56 had confirmed bi-allelic indels and demonstrated increased Ras-GTP pulldown 
and ERK phosphorylation suggestive of activated Ras signalling. ^; clones 1.6 and 1.58 had single allele deletions. 
(F) ID8 Trp53−/−;Pten−/−, Trp53−/−;Nf1−/− and Trp53−/−;Pten+/− cells were irradiated (10 Gy), fixed and stained 
for γH2AX and RAD51, and counterstained with DAPI. RAD51 foci were counted in up to 30 untreated and 
irradiated cells. Bars represent foci per cell (mean +/− SEM); γH2AX (left) and RAD51 (right); dotted lines 
represents two-fold increase in γH2AX and RAD51 foci/cell relative to untreated cells as above.
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and increased resistance to Nutlin-3 compared to cells from a DKO control clone (clone 4) that had been transfected 
with the Trp53 gRNA but contained no Trp53 mutation (Fig. 5A). Both DKO and TKO cells retained functional HR 
(Fig. 5B). However, interestingly, Trp53 loss induced small but statistically significant changes in sensitivity to both 
cisplatin and rucaparib in TKO cells in vitro (Fig. 5C). Loss of p53 function produced a highly significant reduction in 
time to reach humane endpoints - median survival (Fig. 5D; median 34.5 days vs 90 days; p < 0.0001). In vivo, TKO 
tumours demonstrated nuclear WT1 staining (Fig. 5E). However, there was only weak cytoplasmic PAX8 staining, in 
contrast to strong nuclear staining seen in fallopian tube epithelial cells (Fig. 5E).
Figure 3. Generation of triple-deleted Trp53−/−;Brca2−/−;Pten−/− ID8 cells. (A) Immunoblot for PTEN and 
phospho-AKT following overnight serum starvation in clones isolated following Pten gRNA transfection. 
Clones 2.14.22 and 3.15.10, with bi-allelic Pten indels, showed absent PTEN expression and increased 
phosphorylation of AKT at both S473 and T308 compared to the two guide control clones, 2.14.10 and 3.15.7 
that had no detectable change in Pten sequence. (B) ID8 Trp53−/− and Trp53−/−;Brca2−/−;Pten−/− cells were 
irradiated (10 Gy), fixed and stained for γH2AX and RAD51, and counterstained with DAPI. RAD51 foci 
were counted in up to 30 untreated and irradiated cells. Bars represent foci per cell (mean +/− SEM); γH2AX 
(left) and RAD51 (right); dotted lines represent two-fold increase in γH2AX and RAD51 foci/cell relative to 
untreated cells as above.
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Figure 4. In vivo growth of Trp53−/−;Brca1−/−, Trp53−/−;Nf1−/− and Trp53−/−;Pten1−/− ID8 cells; platinum and 
PARP inhibitor sensitivity. (A) Cells (5 × 106) were injected intraperitoneally into female C57Bl/6 mice in groups 
of six. Two different clones were used per genotype for Trp53−/−;Brca1−/−, Trp53−/−;Nf1−/−, Trp53−/−;Pten−/− 
and Trp53−/−;Brca2−/−;Pten−/− tumours: a single clone (F3) was used for Trp53−/−−/− data. Mice were killed 
when they reached humane endpoints. The data for Trp53−/−;Brca2−/− have been published previously14 but are 
presented here for illustrative purposes. (B) Cell sensitivity to PARP inhibition. At least two clones were used per 
genotype, except Trp53−/−, where a single clone (F3) was used. Each dot represents one triplicate experiment. 
Bars represent median. Right; results for Trp53−/−;Brca1−/− by site of mutation - exon 12 (Palb2 domain - clones 
1.26, 1.36) and exon 19 (BRCT-2 domain - clone 6.20), and Trp53−/−;Brca2−/− and Trp53−/−;Brca2−/−;Pten−/− 
cells. ****p < 0.0001, **p < 0.01. (C) Cell sensitivity to cisplatin. At least two clones were used per genotype, 
except Trp53−/−, where the F3 clone was used. Each dot represents one triplicate experiment. Bars represent 
median. Right; results for Trp53−/−;Brca1−/− by site of mutation - exon 12 (Palb2 domain - clones 1.26, 1.36) 
and exon 19 (BRCT-2 domain - clone 6.20) – and for Trp53−/−;Brca2−/− and Trp53−/−;Brca2−/−;Pten−/− cells. 
****p < 0.0001. (D) Cells (5 × 106) were injected intraperitoneally into female C57Bl/6 mice in groups of six. 
Two different clones were used per genotype for Trp53−/−;Brca1−/−, Trp53−/−;Nf1−/− and Trp53−/−;Pten1−/− 
tumours: a single clone (F3) was used for Trp53−/− data. Mice received cisplatin (5 mg/kg) or PBS as 
intraperitoneal injections (200 µl) on days 28, 35 and 42. Mice were killed when they reached humane endpoints.
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Discussion
Here we have extended our previous results, and generated further derivatives of the ID8 murine ovarian car-
cinoma model using CRISPR/Cas9 gene editing. Using one of our previous Trp53−/− clones, we have generated 
further double mutants, with deletions in Brca1, Pten and Nf1 in addition to loss Trp53, as well as triple mutants 
lacking Trp53, Brca2 and Pten. We have also generated a Trp53 mutant derivative of a transplantable murine fallo-
pian tube carcinoma cell line. Collectively, our results indicate that loss of genes known to be mutated or deleted 
in HGSC can alter intraperitoneal tumour growth and response to therapy. Moreover, the responses to therapy 
mirror those seen in patients, reinforcing the utility of these models.
As expected, we show that loss of BRCA1 or BRCA2 function induces defective homologous recombination 
and sensitises cells to both platinum and PARP inhibitor therapy. There was no overall difference in rucaparib 
sensitivity between Brca1−/− or Brca2−/− cells, which accords with results from part 1 of the ARIEL2 trial of ruca-
parib, in which radiological response rates were almost identical in BRCA1 (79%) and BRCA2-mutated (82%) 
tumours8. However, our data show that mice bearing Trp53−/−;Brca2−/− tumours have the longest survival fol-
lowing platinum treatment. It is now clear that patients with germline BRCA2 mutations have significantly greater 
long term survival than patients without mutations and even those with germline BRCA1 mutations6, which may 
reflect extreme sensitivity to platinum-based chemotherapy.
Our results suggest that the location of the mutation within Brca1 might influence sensitivity - the two clones 
with mutations in the PALB2-binding domain were significantly more sensitive to both cisplatin and rucaparib 
in vitro than the BRCT-2 domain mutant, although the difference in survival following in vivo platinum treat-
ment was not significant (p = 0.066). In patients with HGSC, it remains unclear whether the type and location of 
mutations within BRCA1 and BRCA2 influence response to treatment or overall survival. The Australian Ovarian 
Cancer Study found no overall effect of location within the gene, nor of mutation type, on relapse or survival18. 
However, the sample size (n = 134 mutation carriers) was possibly too small to allow enrichment of mutations in 
one specific region. A retrospective analysis of 445 women with germline BRCA1/2 mutations (79% of whom had 
had breast and/or ovarian cancer) found a non-significant (p = 0.06) reduction in overall survival in those with 
BRCA1 exon 20 mutations compared to those with mutations in BRCA1 exons 2 or 1119. However, again the num-
ber of cases with mutation in a specific exon was low. By contrast, in a transgenic murine breast cancer model, 
nonsynonymous missense mutation in the Brca1 RING domain (C61G) was associated with poorer response 
to cisplatin and PARP inhibitor therapy than a complete Brca1 knockout, despite similar tumour morphology 
and copy number alterations20. Large consortia and meta-analyses will help to address genotype/phenotype rela-
tionships, especially relating to survival, but our cells may help to answer specific questions relating to protein 
function and chemotherapy sensitivity, and CRISPR/Cas9 technology allows for further exon-specific deletions 
to be created.
One striking feature of our results was the increased rate of intra-tumoural growth and reduced survival fol-
lowing platinum treatment of tumours with double Trp53;Pten or Trp53;Nf1 mutations compared to those with 
Trp53 mutations alone. Moreover, additional loss of PTEN expression significantly accelerated the growth of 
Trp53−/−;Brca2−/− tumours, and significantly reduced platinum sensitivity in vitro. There are few clear prognostic 
data on the influence of NF1 loss on HGSC patient survival, but our results correlate with data showing that loss 
Genotype
Rucaparib IC50 
(µM) mean +/−  sd p=
Cisplatin IC50 
(µM) mean +/−  sd p=
Trp53−/− 8.23 +/−  0.62 — 1.10 +/−  0.47 —
Trp53−/−;Brca1−/− 0.24 +/−  0.21 <0.01 0.38 +/−  0.22 <0.0001
Trp53−/−;Brca2−/− 0.25 +/−  0.08 <0.01 0.18 +/−  0.03 <0.0001
Trp53−/−;Pten−/− 11.2 +/−  6.94 NS 0.89 +/−  0.21 NS
Trp53−/−;Nf1−/− 4.31 +/−  1.33 NS 0.90 +/−  0.35 NS
Trp53−/−;Brca2−/−;Pten−/− 0.33 +/−  0.12 <0.01 0.28 +/−  0.10 <0.0001
Table 1. Summary of the sensitivity of ID8 clones to rucaparib and platinum. Data represent IC50 averages from 
4–8 triplicate experiments per cell line. IC50 values were compared using one-way ANOVA with Bonferroni’s 
test for multiple comparisons with Trp53−/− cells as comparator.
Genotype
Median survival 
cisplatin (days)
Hazard ratio 
(log-rank) p=
Trp53−/− 81 — —
Trp53−/−;Brca1−/− 97 0.34 0.0003
Trp53−/−;Brca2−/− 113 0.23 <0.0001
Trp53−/−;Pten−/− 69 4.07 <0.0001
Trp53−/−;Nf1−/− 71 3.19 0.0001
Trp53−/−;Brca2−/−;Pten−/− 99 0.29 <0.0001
Table 2. Summary of survival following cisplatin treatment in vivo. Data represent median survival (time to 
reach humane endpoint) for mice bearing ID8 clones treated with cisplatin (5 mg/kg) on days 28, 35 and 42. 
Data were compared using log-rank test.
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of PTEN expression is associated with poor outcome9. We also show clearly that loss of PTEN expression alone 
does not induce defective homologous recombination in ID8 cells, although the additional loss of PTEN does 
not abrogate defective homologous recombination or PARP inhibitor sensitivity seen in Trp53−/−;Brca2−/− cells. 
We found OvidT 497 Dicer−/−;Pten−/− DKO cells to be HR competent, as defined by radiation-induced RAD51 
Figure 5. Generation and evaluation of Dicer−/−;Pten−/−;Trp53−/− TKO cells. (A) OvidT 497 Dicer−/−;Pten−/− 
(DKO) cells were transfected with PX459 encoding Trp53 gRNA. Clone 4 contained no Trp53 mutation; 
clone 13 (TKO) contained bi-allelic Trp53 exon 5 mutations. Expression of PTEN and p53 was assessed 
by immunoblot (left). F3 = ID8 Trp53−/−. Sensitivity to Nutlin-3 was assessed by MTT assay (right). (B) 
Homologous recombination was assessed in DKO 4 and TKO 13 cells as previously. (C) Sensitivity of DKO 4 
and TKO 13 cells to cisplatin. Each dot represents one triplicate experiment. Bars represent median. *p < 0.01. 
(D) Cells (5 × 106) were injected intraperitoneally into female C57Bl/6 mice in groups of six. Mice were killed 
when they reached humane endpoints. Excised tumours were fixed in formalin and stained for WT1 and PAX8. 
Each TKO 13 section comes from a separate mouse. Positive controls (+ve) are ID8 tumour (WT1) and normal 
mouse fallopian tube (PAX8), both from14. Bars represent 50 µm.
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foci formation, and that loss of p53 function in the Dicer−/−;Pten−/−;Trp53−/− TKO cells induced a degree of both 
platinum and PARP inhibitor resistance. This contrasts with data from HCT116 cells21 and from endometrioid 
endometrial carcinoma22, whereby loss of PTEN was associated with partial loss of HR and sensitivity to PARP 
inhibition. In PTEN-deficient prostate carcinoma cells, treatment with a PARP inhibitor induced apoptosis but 
only in the absence of p5323. Overall, these data imply that the relationship between PTEN, p53 and DNA double 
strand break repair is complex and varies by tumour type; however, our results do suggest that classification of 
PTEN-mutant HGSC as HR defective in the absence of mutations in BRCA1 or BRCA24 may be erroneous.
The Dicer−/−;Pten−/−;Trp53−/− TKO cells also demonstrate clearly that loss of p53 function significantly 
enhances intra-peritoneal tumour growth. This is in keeping with our original ID8 work14 and data from the 
Dicer−/−;Pten−/−;Trp53LSL-R172H/+ TKO mice, in which expression of mutant p53 resulted in a more aggressive 
phenotype than Dicer−/−;Pten−/− alone24. Unfortunately, no transplantable cell lines have been described from the 
Dicer−/−;Pten−/−;Trp53LSL-R172H/+ TKO mice with which to allow comparison of tumours lacking p53 expression 
with those harbouring a potential gain-of-function point mutation. One potential criticism of the ID8 model is 
that it is likely to be of ovarian origin, whereas the majority of HGSC cases arise from precursor lesions within the 
distal fallopian tube25,26. The Dicer−/−;Pten−/− DKO represents a novel model of tubal carcinogenesis, although the 
exact cell of origin remains unclear15. Our immunohistochemistry show the DKO and TKO tumours to express 
WT1 but not PAX8, suggesting that they have either lost PAX8 expression during tumorigenesis, or may not arise 
in the secretory cells of the tubal fimbria– interestingly, in transgenic Pten−/−;Trp53LSL-R172H/+ mice, tumours were 
still able to form following removal of the fallopian tumours, suggesting that HGSC can arise in the ovaries24.
In conclusion, we have generated new transplantable murine models that recreate further key mutations of 
HGSC. These cell lines will be powerful tools, alongside transgenic models and primary patient material, to eluci-
date HGSC biology and chemotherapy resistance, and all of the ID8 lines are freely available to other researchers 
upon request.
Materials and Methods
Cells. The production of ID8 Trp53−/− cells was described previously14. OvidT 479 cells were isolated from 
tumours arising in Dicer-Pten double knockout (DKO) mice (Amhr2cre/+ Dicerflox/flox Ptenflox/flox) as previously 
described15,27.
CRISPR/Cas9 and selection. Guide RNAs targeting the PALB2-binding domain in exon 12 and the BRCT-2 
domain in exon 19 of Brca1 were designed using two open-access software programs, CHOPCHOP (https://
chopchop.rc.fas.harvard.edu/) and CRISPR design (http://crispr.mit.edu/), and ligated into BbsI-linearized pSp-
Cas9(BB)-2A-Puro [PX45928, a gift from Feng Zhang via Addgene]. The gRNA for Pten was a gift from Douglas 
Strathdee (CRUK Beatson Institute, Glasgow, UK) and targeted exon 5, encoding the phosphatase domain. The 
gRNA for Nf1 was designed to target exon 2 as previously described29. gRNAs for Pten and Nf1 were ligated into 
PX33030 (a gift from Walter Jackson via Addgene, ref 78621).
Cells were transfected as previously14, omitting puromycin selection for Pten and Nf1 targeting. PCR primers 
spanning target sites of deletion are listed in Table S1. PCR products were cloned using InFusion kit (ClonTech) 
and clones with large PCR deletions were selected for subsequent analysis. Remaining clones were screened using 
the Surveyor Nuclease Assay (Integrated DNA Technology). Mutations were confirmed by Sanger sequencing. All 
sequence alignment was performed using MAFFT version 7 (http://mafft.cbrc.jp/).
γH2AX/Rad51 assay. 24 h treatment following treatment with 10 µM rucaparib (Clovis Oncology, Boulder, 
CO), or following 10 Gy irradiation, cells were fixed and stained for γH2AX and Rad51 foci as previously14 
using a Zeiss 710 confocal microscope and Zen software (Zeiss). Microscope settings were as follows: 20x objec-
tive, 1024 × 1024 frame, 6.25 s scan time. Lasers used were 561 nm (red), 488 nm (green) and 405 nm (DAPI). 
Fluorophores were ALEXA-568 (for RAD51) and ALEXA-488 (for γH2AX). Foci were counted in at least 30 
nuclei per condition without any image manipulation. Images presented in figures were captured from raw Zen 
files using Photoshop CS5 v12.1 software (Abode), and processed in their entirety using the ‘AutoContrast’ tool, 
and then cropped to show single representative cells. Classification of homologous recombination competence 
was performed as previously16.
Immunoblot and co-immunoprecipitation. For detection of phospho-AKT, cells were serum-starved for 
16 hours prior to lysis. Antibodies used were: phospho-AKT (T308) (Cell Signalling 13038), phospho-AKT (S473) 
(Cell Signaling 40600), AKT (Cell Signalling 4685) and PTEN (Cell Signalling 9552). Co-immunoprecipitation 
of Ras-GTP was performed using Ras pulldown activation assay kit (BK008-S; Cytoskeleton, Denver CO, USA). 
5 × 105 cells were plated on 10 cm dishes for 72 hours, then serum-starved for 16 hours prior to lysis. All sub-
sequent steps were performed according to manufacturer’s instructions. The same lysates were probed for 
phospho-ERK (Cell Signalling 4695) and total ERK.
All immunoblot images were acquired using a BioRad ChemiDoc MP imaging system and Image Lab 5.0 
software (both BioRad, Watford UK). Images were visualised using Photoshop CS5 v12.1 software (Abode), and 
processed in their entirety using the ‘AutoContrast’ tool, and then cropped to include relevant lanes only. All 
immunoblot images presented derive from single blots and no Photoshop touch-up tools were used in any image. 
All loading controls come from blots stripped and re-probed.
In vitro cytotoxicity. ID8 cells (3 × 104 cells/well of a 24 well plate) were treated with 3 nM–30 μM rucaparib 
(Clovis Oncology, Boulder CO, USA) or 10 nM–1000 μM cisplatin (Accord Healthcare, Harrow, UK via Beatson 
West of Scotland Cancer Centre chemotherapy pharmacy) 4 hours after initial plating. 68 hours thereafter, cell 
survival was assessed using sulphorhodamine B (rucaparib) or MTT31 (cisplatin) assay.
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In vivo experiments and immunohistochemistry. All experiments complied with the UK welfare 
guidelines32 and were conducted under specific personal and project license authority (70/8645) with ethical 
approval (University of Glasgow) in dedicated animal facilities. 5 × 106 cells were inoculated intraperitoneally 
(IP) in 6–8 week old female C57Bl/6 mice (Charles River Laboratories, UK) in groups of 6. A minimum of two 
clones per genotype were used in all experiments. Mice were monitored regularly and killed upon reaching UK 
Home Office limits. All decisions about animal welfare and experiment endpoints were made by D.A. or S.M. 
independently of main study investigators to prevent bias. Cisplatin (5 mg/kg in 200 µl PBS) or PBS was adminis-
tered intraperitoneally on days 28, 35 and 42 only. Ascites was collected and all visible tumour deposits dissected 
out, and either snap frozen or fixed in neutral-buffered 4% paraformaldehyde. 5 µm sections from formalin-fixed 
paraffin-embedded tumours were stained (Dako Autostainer, Dako, UK). The following antibodies were used for 
immunohistochemistry - WT1 (Can (R9), Abcam, 1:250); PAX8 (ZR-1, Zeta, 1:30). Images were captured on a 
Zeiss Observer Z1 microscope (20x objective) using Zen software (Zeiss), visualised using Photoshop CS5 v12.1 
software (Abode), and processed in their entirety using the ‘AutoContrast’ tool.
Statistics. All analyses were performed using Prism v6.0 (Graphpad, CA). One-way ANOVA with 
Bonferroni’s test for multiple comparisons and unpaired t-test were used to compare IC50 values. Mouse survival 
was compared using the log-rank test. p < 0.05 was considered significant.
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